TY - JOUR T1 - Changes in development and evaluation of new cancer drugs: what is needed to guide practice? JF - European Journal of Hospital Pharmacy: Science and Practice JO - Eur J Hosp Pharm SP - 70 LP - 70 DO - 10.1136/ejhpharm-2012-000073 VL - 19 IS - 2 AU - Wolf-Dieter Ludwig Y1 - 2012/04/01 UR - http://ejhp.bmj.com/content/19/2/70.abstract N2 - Cancer remains an important public health problem in Europe. Due to an ageing population, the total number of new cases of cancer in Europe will continue to increase even if age-specific rates remain constant. There has been a reduction in cancer mortality during the past two decades that could be explained mainly by behavioural changes and screening procedures. At the same time, given a gradual shift from cytotoxic drugs to more or less selective, high-cost targeted therapeutic agents, the price spiral of cancer … ER -